APAC IPOs & Placements

Zhen Zhou, Toh

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Akeso Biopharma Inc / Equity Capital Markets

<a href="https://www.smartkarma.com/entities/akeso-biopharma-inc" target="_blank" data-smartkarma-citation="entities:28830:1" rel="noopener">Akeso Biopharma Inc (9926 HK)</a> is looking to raise about US$154m from its primary placement to fund its expansion plans which includes building a commercialization team, new production facility, and development of other clinical programs.We will focus on deal dynamics, updates since listing, and scores from our ECM framework.<a href="https://www.smartkarma.com/profiles/ke-yan-cfa-frm" target="_blank" data-smartkarma-citation="accounts:9" rel="noopener">Ke Yan, CFA, FRM</a> has previously covered the IPO in:<ul>
<li><a href="https://www.smartkarma.com/insights/akesobio-pre-ipo-late-in-the-pd-1-game-but-products-are-promising" target="_blank" rel="noopener">Akesobio (康方生物) Pre-IPO: Late in the PD-1 Game but Products Are Promising</a></li>
<li><a href="https://www.smartkarma.com/insights/akesobio-pre-ipo-thoughts-on-valuation" target="_blank" rel="noopener">Akesobio (康方生物) Pre-IPO: Thoughts on Valuation</a></li>
<li><a href="https://www.smartkarma.com/insights/akesobio-pre-ipo-clinical-trial-updates-from-phip" target="_blank" rel="noopener">Akesobio (康方生物) Pre-IPO: Clinical Trial Updates from PHIP</a></li>
<li>
<a href="https://www.smartkarma.com/insights/akesobio-ipo-expect-near-zero-allocation" target="_blank" data-smartkarma-citation="insights:38404" rel="noopener">Akesobio (康方生物) IPO: Expect near Zero Allocation</a> </li>
</ul>

Akeso Biopharma Inc (9926 HK) is looking to raise about US$154m from its primary placement to fund its expansion plans which includes building a commercialization team, new production facility, and development of other clinical programs.We will focus on deal dynamics, updates since listing, and scores from our ECM framework.Ke Yan, CFA, FRM has previously covered the IPO in:
Akesobio (康方生物) Pre-IPO: Late in the PD-1 Game but Products Are Promising
Akesobio (康方生物) Pre-IPO: Thoughts on Valuation
Akesobio (康方生物) Pre-IPO: Clinical Trial Updates from PHIP

Akesobio (康方生物) IPO: Expect near Zero Allocation 


Akeso (康方生物) Placement - Prepping for Commercialization